Teva buying rival Ivax for $7.4B

Shares of Ivax were on the rise this morning after Israeli generic drug maker Teva said it would buy the rival US pharmaceutical company for $7.4 billion in cash and stock. Ivax shareholders will get either $26 in cash for each share or .84 of a share in the new company. The combined company will control more than $7 billion in annual sales of generic drugs and have 25,000 employees. The deal -- the latest in a host of mergers and acquisitions to sweep the biopharma industry -- is expected to close late this year or early next.

- read this report from Canada.com for more

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.